Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRAFT: Filgrastim in acute-on-chronic liver failure
NCT02669680Completed
- Sponsor
- Leipzig University
- Start
- Feb 2016
- Primary completion
- Mar 2020
- Countries
- 1
01
Overview
Randomised, open-label trial of filgrastim in acute-on-chronic liver failure (ACLF), sponsored by Leipzig University. Primary endpoint: Transplant-free survival at 90 days. Started Feb 2016; status: completed.
02
Drugs
filgrastim
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT02669680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02669680.